STLN: financial statements from SEC — TradeAlmanac

STLN

Starling Oncology, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	503m	393m
Selling, general and administrative	106m	108m
Operating income	−36m	−60m
Pre-tax income	−61m	−65m
Income tax	−131,000	0
Net income	−61m	−65m
Earnings per share	−0.54	−0.71
Earnings per share, diluted	−0.54	−0.71
Weighted average shares	92m	75m
Weighted average shares, diluted	92m	75m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	30m	34m	28m	30m	40m	50m	47m	36m
Short-term investments	—

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	−25m	−27m
Depreciation and amortisation	7m	6m
Share-based compensation	5m	11m
Capital expenditure	3m	4m
Investing cash flow	−3m	46m
Share buybacks	—

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)